In contrast, GBA1 p.N409S carriers at the top decile for PRS experienced a sevenfold increase in the relative odds of reporting PD compared to noncarriers with median PRS, which may help reduce the number of participants required for GBA1 trials. Here, GBA1 is linked to Parkinson disease.